Baxter International Inc.
$19.97B- Market cap
- $12.50B
- Debt
- +$9.44B
- Cash
- −$1.97B
Capital structure 57% equity / 43% debt · EV / Revenue 1.78x · EV proxy / EBITDA proxy 29.68x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BAX stock price vs TFX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at TFX's multiple
Needs TFX P/S.
Implied fair value · at BAX's multiple
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 57% equity / 43% debt · EV / Revenue 1.78x · EV proxy / EBITDA proxy 29.68x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BAXTER INTERNATIONAL INC. · implied price per share
Bear
-$0.03
Base
$2.03
Bull
$5.72
TELEFLEX INCORPORATED · implied price per share
Bear
-$24.97
Base
-$21.78
Bull
-$16.12
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BAX can sustain revenue growth while repairing operating and net margins, then a selective long position may make sense because the stock trades at a clear P/S discount to TFX and near its historical range; otherwise, the weak profitability profile argues for patience.
BAX trades at 1.3x P/S versus TFX at 3.1x, which helps explain the large valuation gap and the 141.4% implied upside from TFX-based framework. However, both companies are unprofitable on a net basis, so the comparison is being driven more by sales multiples than earnings quality.
Supporting Metrics